PMID- 29844496 OWN - NLM STAT- MEDLINE DCOM- 20191125 LR - 20191210 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 8 IP - 1 DP - 2018 May 29 TI - Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. PG - 8236 LID - 10.1038/s41598-018-26656-2 [doi] LID - 8236 AB - Disruptions in social decision-making are becoming evident in many psychiatric conditions. These are studied using paradigms investigating the psychological mechanisms underlying interpersonal interactions, such as the Ultimatum Game (UG). Rejection behaviour in the UG represents altruistic punishment - the costly punishment of norm violators - but the mechanisms underlying it require clarification. To investigate the psychopharmacology of UG behaviour, we carried out two studies with healthy participants, employing serotonergic agonists: psilocybin (open-label, within-participant design, N = 19) and 3,4-methylenedioxymethamphetamine (MDMA; placebo-controlled, double-blind, crossover design, N = 20). We found that both MDMA and psilocybin reduced rejection of unfair offers (odds ratio: 0.57 and 0.42, respectively). The reduction in rejection rate following MDMA was associated with increased prosociality (R(2) = 0.26, p = 0.025). In the MDMA study, we investigated third-party decision-making and proposer behaviour. MDMA did not reduce rejection in the third-party condition, but produced an increase in the amount offered to others (Cohen's d = 0.82). We argue that these compounds altered participants' conceptualisation of 'social reward', placing more emphasis on the direct relationship with interacting partners. With these compounds showing efficacy in drug-assisted psychotherapy, these studies are an important step in the further characterisation of their psychological effects. FAU - Gabay, Anthony S AU - Gabay AS AUID- ORCID: 0000-0002-6946-1046 AD - Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom. anthony.a.gabay@kcl.ac.uk. FAU - Carhart-Harris, Robin L AU - Carhart-Harris RL AD - Psychedelic Research Group. Neuropsychopharmacology Unit. Centre for Academic Psychiatry, Imperial College London, London, United Kingdom. FAU - Mazibuko, Ndaba AU - Mazibuko N AD - Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom. FAU - Kempton, Matthew J AU - Kempton MJ AD - Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom. AD - Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom. FAU - Morrison, Paul D AU - Morrison PD AD - Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom. FAU - Nutt, David J AU - Nutt DJ AD - Psychedelic Research Group. Neuropsychopharmacology Unit. Centre for Academic Psychiatry, Imperial College London, London, United Kingdom. FAU - Mehta, Mitul A AU - Mehta MA AD - Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20180529 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 2RV7212BP0 (Psilocybin) RN - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine) SB - IM MH - Adult MH - Altruism MH - Community-Based Participatory Research MH - *Decision Making MH - Emotions MH - Games, Experimental MH - Healthy Volunteers MH - Humans MH - *Interpersonal Relations MH - Male MH - Middle Aged MH - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage MH - Psilocybin/*administration & dosage MH - Psychopharmacology/methods MH - Punishment/*psychology MH - Rejection, Psychology MH - Reward MH - *Social Behavior MH - Socialization MH - Young Adult PMC - PMC5974271 COIS- The authors declare no competing interests. EDAT- 2018/05/31 06:00 MHDA- 2019/11/26 06:00 PMCR- 2018/05/29 CRDT- 2018/05/31 06:00 PHST- 2018/03/29 00:00 [received] PHST- 2018/05/15 00:00 [accepted] PHST- 2018/05/31 06:00 [entrez] PHST- 2018/05/31 06:00 [pubmed] PHST- 2019/11/26 06:00 [medline] PHST- 2018/05/29 00:00 [pmc-release] AID - 10.1038/s41598-018-26656-2 [pii] AID - 26656 [pii] AID - 10.1038/s41598-018-26656-2 [doi] PST - epublish SO - Sci Rep. 2018 May 29;8(1):8236. doi: 10.1038/s41598-018-26656-2.